Login
News
31.07.2019 July 2019: Fatal events occurring during study treatment: a pooled analysis of death cases within GBG led breast cancer trials
We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer
Mehr ...08.07.2019 Fortbildung Checkpoint-Inihibitoren
Fortbildungsveranstaltung „Behandlung mit Checkpoint-Inihibitoren“ der GBG und des BreastNet Rhein Main am 27. August 2019 von 17:00 – 20:00 Uhr in Frankfurt
Mehr ...04.07.2019 June 2019: Clinical results and biomarker analysis of the randomised phase II GeparNuevo study
We are pleased to inform you that the results of the randomised phase II GeparNuevo (GBG 89) study that aimed to investigate the addition of durvalumab, a human monoclonal antibody targeting programmed cell death ligand-1 (PD-L1) to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer (TNBC) have been published in the Annals of Oncology.
Mehr ...03.06.2019 May 2019: Long-term outcomes of the GeparSepto study
The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.
Mehr ...